A global comparative study on real-world clinical and genomic differences in advanced biliary tract cancer. Extra-hepatic (ehCCA) and intra-hepatic cholangiocarcinomas (iCCA): A genomic landscape ...

Compass Therapeutics recently reported that its Phase 2/3 COMPANION-002 trial in previously treated advanced biliary tract cancer met the primary endpoint, with tovecimig plus paclitaxel achieving ...

Tovecimig (CTX-009) in combination with paclitaxel significantly improved progression-free survival (PFS), but not overall ...

Findings showed that pembrolizumab plus chemotherapy reduced the risk of death by 17% compared with chemotherapy alone. The Food and Drug Administration (FDA) has approved Keytruda ® (pembrolizumab) ...

Results showed the ORR was 17.1% in the tovecimig plus paclitaxel arm compared with 5.3% in the paclitaxel alone arm. Topline data were announced from a phase 2/3 trial evaluating tovecimig in ...

Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...

Shares of Compass Therapeutics rose after the company said it would host a webcast to review data from its Phase 2/3 study of a potential treatment for advanced biliary tract cancer. The stock gained ...

ctDNA is a valuable prognostic biomarker for relapse in early-stage BTC, outperforming carbohydrate antigen 19-9 levels. ctDNA monitoring can detect molecular recurrence earlier than standard ...

Acute cholangitis is a severe, bacterial infection of the biliary tract precipitated by an obstruction that often results in systemic inflammation and, in some cases, life‐threatening sepsis. This ...

Compass Therapeutics says a treatment evaluating its cancer treatment didn’t meet the secondary endpoint for an unexpected ...

The US Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for locally advanced unresectable or metastatic biliary tract cancer in combination with gemcitabine and cisplatin.

UK MHRA approves GSK’s Linerixibat for the treatment of itch due to biliary tract disease: United Kingdom Monday, May 4, 2026, 09:00 Hrs [IST] The Medicines and Healthcare produ ...